Meeder Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Meeder Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9	Closed	-$28	–	541
2023 Q3	$28	Sell	9 -1	-10%	-$4	﹤0.01%	483
2023 Q2	$45	Hold	10	–	–	﹤0.01%	499
2023 Q1	$69	Hold	10	–	–	﹤0.01%	587
2022 Q4	$63	Hold	10	–	–	﹤0.01%	782
2022 Q3	$0	Sell	10 -22	-69%	-$381	﹤0.01%	2297
2022 Q2	$0	Sell	32 -6	-16%	-$136	﹤0.01%	2356
2022 Q1	$1K	Buy	+38	New	+$1.22K	﹤0.01%	2221
2021 Q4	–	Sell	-197	Closed	-$14K	–	1961
2021 Q3	$14K	Hold	197	–	–	﹤0.01%	1558
2021 Q2	$23K	Buy	197 +9	+5%	+$879	﹤0.01%	1419
2021 Q1	$20K	Buy	+188	New	+$17.9K	﹤0.01%	1404
2020 Q4	–	Sell	-186	Closed	-$3K	–	2115
2020 Q3	$3K	Hold	186	–	–	﹤0.01%	1741
2020 Q2	$7K	Hold	186	–	–	﹤0.01%	1428
2020 Q1	$9K	Buy	186 +141	+313%	+$6.91K	﹤0.01%	1563
2019 Q4	$2K	Sell	45 -2	-4%	-$72	﹤0.01%	2039
2019 Q3	$2K	Buy	+47	New	+$1.85K	﹤0.01%	1974
2018 Q1	–	Sell	-1	Closed	–	–	1689
2017 Q4	$0	Buy	+1	New	+$113	﹤0.01%	1756

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's IMDX Position: Q4 2023 in Review

Meeder Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2023, closing a stake of 9 shares — an estimated $28 sold.

Meeder Asset Management first reported a position in IMDX in Q4 2017 and held it in 16 quarters. The position peaked at $23K in Q2 2021. 26 funds tracked by Wall St. Rank hold IMDX as of Q4 2023.

Meeder Asset Management reported no remaining Insight Molecular Diagnostics position as of Q4 2023 after selling out during the quarter.
Meeder Asset Management sold 9 Insight Molecular Diagnostics shares in Q4 2023, an estimated $28.
Meeder Asset Management first reported a position in Insight Molecular Diagnostics in Q4 2017 and held it in 16 quarters.
Meeder Asset Management's Insight Molecular Diagnostics position peaked at $23K in Q2 2021.
26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2023.

Based on Meeder Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.